September 11, 2026 FDA Approves Isembyld as First Muscle-Targeted Treatment for Spinal Muscular Atrophy
June 18, 2026 FDA Approval Path Opens for Breakthrough Huntington’s Disease Gene Therapy – New Hope for Patients
